Determination of vancomycin exposure target and individualized dosing recommendations for ICU neonates: model informed precision dosing

Zhe Tang[1], Jing Guan[1], Jingjing Li[2], Yanxia Yu[2], Miao Qian[3], Jiang Cao[1], Weiwei Shuai[1], Zheng Jiao[4,*]

[1]Department of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China

[2]Department of Pharmacy, Suzhou Municipal Hospital, Suzhou, China

[3]Department of Neonatology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China

[4]Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Running Head: exposure target of vancomycin for neonates

*Correspondence author
Zheng Jiao, jiaozhen@online.sh.cn
ORCID: 0000-0001-7999-7162
Tel: 8621 2220 0000 ext 3021
Fax: 8621 2220 0000 ext 3021
Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University
241 Huai-hai West Road, 200030, Shanghai, China.

Abstract

Background: Few studies incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modeling have been conducted to quantify the exposure target of vancomycin in neonates.

Objectives: (i) to derive vancomycin exposure target considering both vancomycin-induced acute kidney injury (AKI) and clinical efficacy in ICU neonates; (ii) to optimize dosing regimen of vancomycin in neonates based on PK/PD modeling and simulation.

Methods: This retrospective observational cohort study was registered at chictr.org.cn (ChiCTR1900027919). A Pop-PK model was developed to estimate individual PK parameters. Thresholds of vancomycin exposure in predicting AKI or efficacy were identified via classification and regression tree (CART) analysis. The association between exposure thresholds and clinical outcomes including AKI and efficacy was detected by logistic regression. Dosing recommendations were designed using Monte Carlo (MC) simulations based on the optimized exposure target.

Results: There were 182 neonates with 411 observations included in Pop-PK modeling. Covariate analysis showed that neonatal physiological maturation, renal function and conmitant use of vasoactive drugs (VAS) significantly affected vancomycin pharmacokinetics. AKI were screened for all patients. $AUC_{0\text{-}24}$≥485 mg·h/L was an independent risk factor for AKI when adjusting for co-administration of VAS. Clinical efficacy of vancomycin was analyzed in 42 patients with blood culture-proved staphylococcal sepsis. $AUC_{0\text{-}24}$/MIC≥234 was the only significant predictor for clinical

effectiveness. MC simulations indicated that regimens in Neonatal Formulary 7 and Red Book (2018) were not suitable for all the neonates.

Conclusions: $AUC_{0\text{-}24}$ of 240~480 assuming MIC=1 mg/L is a recommended exposure target of vancomycin in neonates. The model informed dosing regimens are valuable in clinical practice.

Key words: vancomycin, neonate, population pharmacokinetic modeling, acute kidney injury, efficacy, AUC

Introduction

Neonates are predisposed to late-onset sepsis owing to their compromised immunity. *Staphylococcus aureus* and *other Staphylococcus spp.* are the predominant pathogenic bacteria. Vancomycin is the first-line choice against staphylococcal sepsis for ICU neonates[1].

Recent consensus guideline[2] supports a Bayesian-derived AUC/MIC of 400 to 600 (assuming MIC=1 mg/L) as the vancomycin exposure target for adults infected by MRSA. Bayesian-derived AUC monitoring is advocated while trough target-based dosing is not recommended given that an identical trough value can be derived from a wide range of daily AUC values[2, 3].

Several published reports in adults have examined vancomycin exposure-outcome relationship incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modeling[4-9]. Comparatively, few exposure-outcome evaluations have been conducted in neonates[10]. Vancomycin is known as a potential nephrotoxin. However, its exposure threshold associated with vancomycin-induced acute kidney injury (AKI) has not been clearly defined in neonates[10]. The association between vancomycin exposure and clinical efficacy fails to be clarified in this population either[11]. Thus, there is a critical need for clinical studies in neonates that associate individual exposure with clinical outcomes incorporating AKI and efficacy.

This study aimed: (i) to derive vancomycin exposure target that balances both AKI and efficacy in ICU neonates, with a focus on AUC/MIC; (ii) to optimize neonatal dosing

recommendations of vancomycin by using Monte Carlo (MC) simulation according to the exposure target obtained and the established Pop-PK model.

Patients and methods

Ethics

A retrospective observational cohort study was conducted and executed in accordance with the recommendations of the Declaration of Helsinki (2000). The protocol was approved by the Ethics Committee of Nanjing Maternity and Child Health Care Hospital. Identities of patients were hidden during the study. Informed consent was approved unnecessary due to retrospective nature of the study. This study was registered at chictr.org.cn (ChiCTR1900027919).

Study population

The electronic medical records of patients who accepted vancomycin treatment in neonatal ICU from 1st January 2016 to 31st December 2019 were reviewed to determine eligibility. Patients with postmenstrual age (PMA)≤48 weeks when vancomycin initiated were included. All individuals with normal renal function were treated by vancomycin for ≥3 days with at least one vancomycin serum concentration monitored. The exclusion criteria included patients with incomplete data or vancomycin serum concentrations below the limit of detection and patients with baseline serum creatinine (SCR) ≥81 μmol/L[12] prior to vancomycin treatment.

Information of interest included: demographic information, dosing history, vancomycin serum concentration, SCR, creatinine clearance (CLCR), co-medications, clinical diagnosis, radiographic examinations, and microbiological culture. CLCR was calculated by Schwartz equation[13] (Equation 1) as below:

$$\mathrm{CLCR}\ [(\mathrm{ml}\cdot\mathrm{min}^{-1})/1.73\mathrm{m}^2\ ] = \frac{K\times HT(cm)\times 92.83}{SCR(\mu mol/L)+10.79} \quad (1)$$

Where HT is body length of neonates, SCR is serum creatinine and K is a constant equal to 0.33 (preterm neonates with PMA<37 weeks) or 0.45 (term neonates with PMA≥37 weeks).

According to the local protocol, neonates with suspected or confirmed sepsis received empirical therapy with vancomycin in combination with meropenem based on presumptive diagnosis. Once a diagnosis was established, anti-infectives were rationalized to cover the causative pathogen.

Vancomycin (Vancocin, Lilly, S.A, Suzhou, China) was administered 10~15 mg/kg every 8 to 18 h with intermittent infusion lasting 60 min. Blood samples were collected 0.5 h before vancomycin administration (trough) or 0.5 h after infusion completion (peak) prior to the fourth or fifth dose. Target trough levels were 10 to 20 mg/L[14].

Bioanalytical method

Vancomycin concentrations were analyzed by fluorescence polarization immunoassay with an ARCHITECT i2000SR (Abbott Laboratories, Chicago, IL, USA) within 24 h after samples obtained. The limit of detection was 1 mg/L, and the calibration range was 3 to 100 mg/L. The intra-day and inter-day coefficients of variation (CV) were less than 20%.

SCR were analyzed through enzymatic method (Beckman Coulter AU5800, Beckman Coulter Inc., Brea CA, USA) with linearity from 5 to 13275 μmol/L. The intra-day and inter-day CVs were less than 5%.

Etiological examinations were provided by clinical laboratory of our hospital using VITEK 2 microbial identification system (bioMérieux, Lyon, France). The broth microdilution (BMD) method was used to determine MICs. The interpretative reports were issued by laboratory technicians according to CLSI criteria[15].

Pop-PK modeling

A Pop-PK model was developed to estimate PK parameters by nonlinear mixed effect modeling software Monolix (version 2019R2, Lixoft, France) with Stochastic Approximation Expectation Maximization (SAEM) algorithm.

One or two compartment model with first-order elimination was examined to fit the dataset. Interindividual variabilities of PK parameters were estimated using an exponential model. Residual unexplained variabilities were tested by an additive model, an exponential model, or a combined additive and exponential model. Potential covariates were screened and concomitant medication present in less than 20% population was not going to be tested.

Five models were employed to describe the impacts of size (weight) and maturation (age) on clearance (CL) (Table S1)[16-18]. The model with lowest Akaike information criteria (AIC) and Bayesian information criteria (BIC) as well as appropriate estimates of parameter was employed for further analysis[19]. The selection of covariates was determined using a forward inclusion and a backward elimination process. Nested covariate models were statistically compared using a likelihood ratio test on differences in the objective function

value (OFV). A reduction in OFV of 3.84 ($p<0.05$) for forward inclusion and an increase in OFV of 6.63 ($p<0.01$) for backward elimination were the criteria for retaining a covariate in the model.

The final model was internally assessed by visual inspection of goodness-of-fit plots, normalized prediction distribution error (NPDE), and bootstrap[19-21]. The data from the previous study by Li et al.[22] was used to validate the final model externally. The mean prediction error (MPE) and mean absolute prediction error (MAPE) (Table S2) were applied to calculate bias and imprecision of model predictions[23].

Estimation of individual exposure variables

Individual exposure variables for initial 48 h of vancomycin therapy, including day 1 AUC (AUC_{0-24}), day 2 AUC (AUC_{24-48}), and cumulative day 1 and 2 AUC (AUC_{0-48}), were estimated by Simulx (version 2019R2, Lixoft, France). Although no data on which AUC (i.e: initial AUC or AUC at steady state (AUC_{ss})) to use in determining vancomycin exposure target, exposure of initial therapy may be more appropriate because potential influence on vancomycin CL by worsening of infection could be avoided, and AUC in first 48 h is critical for ICU neonates and has been associated to clinical outcomes in adults[9, 24].

Determination of the exposure target

(i) AKI analysis. AKI were screened for all patients. AKI definition included an increase of SCR by 26.5 μmol/L within 48 h, or a SCR rise to ≥1.5 times from the baseline within 7 days, or a urine volume <0.5 ml/(kg·h) for 6 hours[25].

(ii) Efficacy analysis. The clinical efficacy was analyzed for patients with blood culture-proved staphylococcal sepsis. Exclusion criteria were: vancomycin treatment ≤5 days, polymicrobial infection or concomitant use of an antibiotic sensitive to the identified staphylococcus. Vancomycin treatment failure was defined as positive blood culture at ≥5 days after initiation of treatment, recurrence of bacteremia within 30 days, or 30-day mortality[5, 7, 24].

Thresholds of vancomycin exposure in predicting AKI or efficacy were derived using classification and regression tree (CART) analysis (R package rpart, version 4.1-15). The predictive performance of thresholds, comprising the CART-derived and other priori defined ones, were evaluated using receiver operating characteristic (ROC) curves, along with predictive matrices including negative and positive predictive values (NPV and PPV, respectively) (R package pROC, version 1.16.2)[9, 26].

Logistic regression analyses were performed to quantify the association between vancomycin exposure and clinical outcomes. Other potential confounding variables with P <0.20 in the univariate analysis were included in multivariate analyses using a stepwise approach and retained in the model[27]. If mutiple variables were correlated, only one of them was tested. P values of ≤0.05 were considered statistically significant.

According to analyses of AKI and efficacy, the optimized exposure target was set as the basis for the following dosing regimen design.

Model informed dosing regimen

Dosing regimens were designed and compared with recommendations in Neonatal Formulary 7[28] and Red Book (2018)[29]. Virtual patients with different physiological

characteristics were employed for MC simulations. Demographic information was obtained from Fenton growth chart[30]. 1000 replicates of each scenario were simulated to detect the most proper scheme (R package mlxR, version 2.0.2).

Results

Study population

One hundred and eighty-five neonates diagnosed as neonatal sepsis received intermittent intravenous infusion of vancomycin in our institution from 1st January 2016 to 31st December 2019. There were 182 patients eligible for this study with 286 trough and 125 peak concentrations (Table S3). Two patients with incomplete data and one patient of hematological malignancy were excluded (Figure 1).

Pop-PK modeling

A Pop-PK model was developed to estimate individual parameters. One compartment model with first-order elimination was sufficient to fit the data. Proportional model was chosen to describe residual unexplained variabilities. The detailed modeling process was summarized in Table S4.

Both Model II with PMA and Model III had relatively lower AIC and BIC. Model II with PMA was selected because of its simplicity. SCR, CLCR, and co-administration of vasoactive drugs (VAS) were recognized as significant covariates on CL. Since SCR and CLCR were correlated and performed equally, SCR was retained due to better clinical accessibility. A 14% decrease in CL was associated with co-administration of VAS.

Moreover, current weight (cWT) was incorporated to the volume of distribution (V) for physiological plausibility. The results of final model were listed in Table 1.

The goodness-of-fit plot of the final model showed no obvious bias or trend (Figure 2). Results of NPDE generally satisfied the hypothesis of normal distribution (Figure 3). The bootstrap analysis (n=2000) showed the final model was precise since the median parameter estimates were close to those of the final model (Table 1).

Twenty-eight patients from the previous study by Li et al.[22] were included for the external evaluation. All the observations were troughs. The medians for cWT, PMA, and SCR were 1.66 kg (range, 0.80 to 2.52 kg), 33.22 weeks (range, 28.28 to 36.71 weeks), and 35.42 μmol/L (range, 14.17 to 51.71 μmol/L) respectively. No one was co-mediated with VAS. The MPE and MAPE for the final model were 3.97% (standard deviation, 19.88%) and 13.01% (standard deviation, 15.36%) respectively.

Since the external evaluation showed no obvious bias, we combined all the data to re-estimate the PK parameters. The estimates did not show an apparent difference (Table S5).

Determination of the exposure target

(i) AKI analysis. Seven AKI cases were identified in total. Five occurred in day 3 after vancomycin initiated, and two in day 4. VAS, which were prescribed to 39 patients, was the major potential nephrotoxin besides vancomycin. VAS referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution. Six in seven AKI cases were co-administered VAS.

Once AKI occurred, vancomycin dosages were adjusted immediately. Except for two deaths, renal function improved among the other five AKI patients within five days of therapy.

Patients who experienced AKI had higher baseline SCR and lower CLCR. Although there was no statistical difference in daily dose between patients with and without AKI, AKI patients had significantly higher vancomycin exposure quantified by $AUC_{0–24}$, $AUC_{24–48}$ and $AUC_{0–48}$ owing to their decreased vancomycin CL. (Table 2).

In ROC curve analysis, AUC_{0-24}, AUC_{24-48}, and AUC_{0-48} significantly predicted AKI with good performance (Figure 4(a)). The CART-derived threshold of AUC_{0-24}≥485 mg·h/L had the highest predictive value with an area under ROC curve (AUC_{ROC}) of 0.74 (CI: 0.54, 0.94) (Table S6). PPV, which represented true-positive predictions of patients who experienced AKI, was positively correlated with vancomycin exposure. When AUC_{0-24}≥485 mg·h/L, PPV increased more rapidly indicating additional risk of incidence of AKI (Table S6). Therefore, this threshold was included in further multivariate regression analysis.

In univariate regression analysis, PNA, persistent pulmonary hypertension of newborn (PPHN), and concomitant use of VAS or furosemide were identified as potential confounding factors that influenced AKI besides AUC_{0-24} (Table S7). Vancomycin trough was not included in multivariate analysis because it was strongly correlated with AUC_{0-24} (Spearman coefficient = 0.75, $P < 0.01$). SCR and CLCR were also excluded as they were included in the diagnostic criteria for AKI. In multivariate regression analysis, AUC_{0-}

$_{24}$≥485 mg·h/L was independently associated with AKI while adjusting for concomitant use of VAS (Table 3).

(ii) Efficacy analysis. Seventy-nine patients had positive blood cultures. Thirty-one with blood culture-proved non-staphylococcal sepsis, 4 with polymicrobial infections, and 2 with co-administration of an antimicrobial that affected the identified staphylococcal species were excluded. Forty-two patients with blood culture-proved staphylococcal sepsis were eligible for efficacy analysis (Figure 1). Sixteen of them were infected by *S. aureus*, while the others by *other Staphylococcus spp.*

Seven patients experienced treatment failures. Three died during vancomycin treatment. Four had positive blood culture results at ≥5 days after initiation of vancomycin, and linezolid was served as an alternative. No one experienced a recurrence of bacteremia. Despite insignificant difference in daily dosage and MICs between patients with and without effective treatment, vancomycin exposures were much lower among ineffective patients quantified by $AUC_{0–24}$/MIC, $AUC_{24–48}$/MIC and $AUC_{0–48}$/MIC (Table 2).

ROC analyses showed that $AUC_{0–24}$/MIC, $AUC_{24–48}$/MIC and $AUC_{0–48}$/MIC performed well in prediction of efficacy (Figure 4(b)). The threshold of AUC_{0-24}/MIC≥234 had the highest predictive value with AUC_{ROC} of 0.86 (CI: 0.71, 1.00) (Table S8). NPV, which referred to true-negative predictions of patients who experienced treatment failure, was negatively correlated with vancomycin exposure. When AUC_{0-24}/MIC≥234, PPV maintained low indicating decreased risk of treatment failure (Table S8). That is why this threshold was included in further analysis.

bWT and cWT were identified as potential confounding factors that influence efficacy besides AUC_{0-24}/MIC by univariate regression analysis (Table S7). These two variables were apparently correlated. cWT was included in multivariate analyses since it better reflected the actual physiological status during vancomycin treatment. In multivariate regression analysis, AUC_{0-24}/MIC≥234 was the only significant factor associated with efficacy (Table 3).

According to analyses above, the exposure target for vancomycin in neonates was set as AUC_{0-24} of 240 to 480 with MIC assumed to 1 mg/L.

Model informed dosing regimen

The dosage recommendations by the references[28, 29] and this study were displayed in Table S9 and Table 4 respectively.

Generally, patients with concomitant use of VAS required a reduced daily dose. The dosing interval of every 24 h was suitable for extremely preterm patients (PMA<28 weeks) with a dose of 12.5~20 mg/kg. For preterm patients with a PMA between 28 and 36 weeks, proper dosing intervals varied from 12 to 24 h. Term neonates (PMA≥37 weeks) required dosing intervals between 8 and 12 h. Dosing intervals ≤8 h was unnecessary.

Our results suggested that the daily dose for extremely-low-birth-weight (ELBW) neonates (cWT<1 kg) was 12.5 to 20 mg/kg. However, Neonatal Formulary 7[28] recommended a daily dose of 20 mg/kg for all ELBW neonates. The maximum daily dose recommended by Red Book (2018)[29] for these patients was 30 mg/kg. Quite a few of ELBW neonates were obviously overdosed in these references. Table 4 also showed that a daily dose of 20 to 45 mg/kg was required for normal-birth-weight (NBW) neonates with cWT>2.7 kg and

SCR≤60 μmol/L. While Red Book (2018)[29] claimed a daily dose of 30 mg/kg for patients (GA>28 week) with normal renal function (SCR< 61.7 μmol/L). Apparently, this regimen was unable to satisfy the treatment needs for all NBW neonates.

Discussion

This is the first study in neonates uniquely utilizing Pop-PK/PD modeling with Bayesian estimation to evaluate vancomycin exposure associated with clinical outcomes including AKI and efficacy. With Bayesian estimation, PK/PD variability for vancomycin exposure-outcomes evaluations is plausible to be quantified. Bayesian estimation also allows for more accurate and reliable quantification of exposure parameters (i.e: AUC) with sparse data. Moreover, using Pop-PK based MC simulations, dosing recommendations for neonates can be derived based on the optimized exposure target.

The exposure threshold for vancomycin-induced AKI in neonates has been clearly defined in this study for the first time. The threshold for AKI, $AUC_{0\text{-}24}$ of 480 mg·h/L, is relatively lower than previous report in children. Le et al.[31] suggests that AUC_{ss} over 24 h in children should be less than 800 mg·h/L to minimize AKI risk. The time to AKI in Le's study ranged from 1 to 15 days[31]. The reported threshold based on AUC_{ss} is probably inapplicable in clinical practice because AKI may occur prior to steady state. AUC after the occurrence of AKI is an inappropriate predictor for AKI because high exposure is not the cause of AKI but the consequence.

In this study, concomitant use of VAS is not only a significant covariate on vancomycin CL, but also a confounding factor in predicting AKI. Six in seven patients who experienced

AKI were co-mediated with VAS. Given that VAS has been reported as an independent risk factor for the development of AKI among ICU neonates[32], vancomycin-induced AKI is probably not only associated vancomycin exposure alone[2, 8, 9, 33]. Multivariate regression analyses show high vancomycin exposure ($AUC_{0\text{-}24}$≥485 mg·h/L) remains an independent predictor of AKI after adjusting for concomitant use of VAS. Although our study cannot explain whether the threshold for AKI will change as a result of concomitant VAS use, there is a reason to believe high vancomycin exposure in addition to VAS application contributes to incidence of AKI.

Another point worth mentioning is renal functions of all AKI patients recovered with the development of vancomycin treatment except two deaths, although they were under a high vancomycin exposure when AKI occurred. Dosing regimens were adjusted without delay and no other adverse reactions (ADR) were observed during their hospital stay. These findings agree with previous pediatric report[34]. It indicates that neonates may be relatively tolerant to high vancomycin exposure and vancomycin-induced renal impairments are possibly reversible. The ongoing monitoring of both vancomycin serum concentrations and SCR needs to be emphasized in clinical practice.

The lower limit of our exposure target is far below the lower limit for adults in recent consensus guideline (AUC/MIC of 240 vs. 400)[2]. Considering that AUC/MIC of ≥300 or ≥400 did not show improved clinical effectiveness in neonates with staphylococcal sepsis in the previous report by Padari et al.[11], it indicates that a lower AUC/MIC is still possible to be effective for neonates. In the absence of other efficacy data in neonates to clarify AUC/MIC necessary for clinical effectiveness against staphylococcal sepsis, the threshold for efficacy needs to be validated in the furture.

The relationship between vancomycin exposure and clinical efficacy failed to be discovered in previous pediatric and neonatal studies[11, 35]. In contrast, we found AUC_{0-24}/MIC≥234 was strongly correlated with efficacy. Possible reasons for this disparity may be caused by several factors. Primarily, the previous study by Hahn et al.[35] focus on patients with various sites of infection while all patients in our study have bloodstream infection. Considering several breakpoints reported by studies on different infectious diseases in adults[4-7], the threshold of vancomycin exposure may be infectious site-dependent. Secondly, the whole population of the previous study by Padari et al.[11] had a relatively low vancomycin exposure with only 12% of patients achieved AUC/MIC≥400 compared to 26% in our study. The correlation between efficacy and AUC/MIC may be unable to be detected due to AUC/MIC values concentrated within a narrow range.

In contrast to regimen designed in this study, dose recommendations in current referential books are unsuitable for all neonates. The scheme of Neonatal Formulary 7[28] is merely PMA-based while the regimen of Red Book (2018)[29] is based on GA and SCR. According to our Pop-PK model, renal function and concomitant use of VAS are significant covariates on CL and must be considered in regimen design. Furthermore, regimens in both references[28, 29] are overdosed to ELBW neonates and the regimen of Red Book (2018)[29] is inadequate for NBW neonates with normal renal function.

There are several limitations to our study. Firstly, our data were derived from a homogeneous neonatal population who had bloodstream infection and were administered vancomycin with intermittent infusion. Therefore, the optimized exposure target should be extrapolated to other populations who may have different infection sites with caution. Secondly, given the low morbidity of vancomycin-induced AKI[36] and high effective rate

of staphylococcal sepsis in neonates[2, 37], it is important to recognize that the optimized exposure target has limited ability to predict AKI or efficacy. This target can only serve as a guide that balances AKI and efficacy[9]. Finally, the sample size of this study is relatively small. Our findings need to be validated further in large multi-centered prospective studies.

In conclusion, the exposure target of $AUC_{0\text{-}24}$ of 240 to 480 assuming MIC=1 mg/L should be advocated to achieve clinical efficacy while minimizing ADR for vancomycin treatment in neonates. The model informed dosing regimens are valuable in clinical practice for ICU neonates with staphylococcal sepsis.

Acknowledgements

We thank Dr Xiaohui Chen and other pediatricians from neonatal ICU of Nanjing Maternity and Child Health Care Hospital. We are also grateful to Dr Xiaojun Ji (Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, China) for his assistance with figure preparation.

Funding

This project was supported by Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association (No. 2019YX004).

Transparency declarations

None to declare.

Author contributions

Z.T. and Z.J. planned and organized this study. J.C. and WW.S. were responsible for bioanalytical analysis. M.Q. reviewed the eligibility of patients. JJ.L. and YX.Y. provided the data set for external validation. J.G. performed data management. Z.T. conducted the pharmacokinetic analysis/simulations and wrote the first versions of the manuscript, reviewed by Z.J. All authors revised and accepted the final version.

Supplementary data

Tables S1 to S9 are available as Supplementary data at JAC Online.

References

1. Jacqz-Aigrain E, Zhao W, Sharland M et al. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. *Semin Fetal Neonatal Med* 2013; **18**: 28-34.

2. Rybak MJ, Le J, Lodise TP et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm* 2020.

3. Patel N, Pai MP, Rodvold KA et al. Vancomycin: we can't get there from here. *Clin Infect Dis* 2011; **52**: 969-74.

4. Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. *Antimicrobial agents and chemotherapy* 2012; **56**: 634-8.

5. Gawronski KM, Goff DA, Jack B et al. A Stewardship Program's Retrospective Evaluation of Vancomycin AUC24/MIC and Time to Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis. *Clinical Therapeutics* 2013; **35**: 772-9.

6. Casapao AM, Lodise TP, Davis SL et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. *Antimicrob Agents Chemother* 2015; **59**: 2978-85.

7. Song KH, Kim HB, Kim HS et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. *International journal of antimicrobial agents* 2015; **46**: 689-95.

8. Chavada R, Ghosh N, Sandaradura I et al. Establishment of an AUC 0–24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia. *Antimicrob Agents Chemother* 2017; **61**: e02535-16.

9. Zasowski EJ, Murray KP, Trinh TD et al. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. *Antimicrobial agents and chemotherapy* 2018; **62**.

10. Jacqz-Aigrain E, Leroux S, Zhao W et al. How to use vancomycin optimally in neonates: remaining questions. *Expert Rev Clin Pharmacol* 2015; **8**: 635-48.

11. Padari H, Oselin K, Tasa T et al. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? *BMC Pediatr* 2016; **16**: 206.

12. Avner ED, Niaudet P, Emma F et al. Pediatric Nephrology. London, UK: Springer-Verlag Berlin Heidelberg 2016; 615-6.

13. Schwartz GJ, Brion LP, Spitzer A. The Use of Plasma Creatinine Concentration for Estimating Glomerular Filtration Rate in Infants, Children, and Adolescents. *Pediatric Clinics of North America* 1987; **34**: 571-90.

14. Ye Z-K, Chen Y-L, Chen K et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. *Journal of Antimicrobial Chemotherapy* 2016; **71**: 3020-5.

15. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. *CLSI supplement M100*. Pennsylvania, USA: Wayne, 2020; 58-9.

16. Wang C, Peeters MY, Allegaert K et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. *Pharm Res* 2012; **29**: 1570-81.

17. Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. *J Pharm Sci* 2013; **102**: 2941-52.

18. Ding J, Wang Y, Lin W et al. A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation. *Clin Pharmacokinet* 2014; **54**: 305-17.

19. Byon W, Smith MK, Chan P et al. Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance. *CPT Pharmacometrics Syst Pharmacol* 2013; **2**: e51.

20. Ette EI. Stability and performance of a population pharmacokinetic model. *J Clin Pharmacol* 1997; **37**: 486-95.

21. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. *Comput Methods Programs Biomed* 2008; **90**: 154-66.

22. Li JJ, Liu YX, Tang L et al. Population Pharmacokinetics of Vancomycin in Chinese Neonates. *Chin Pharm J* 2017; **52**: 1434-41.

23. van der Meer AF MM, Touw DJ, Proost JH, Neef C. Optimal Sampling Strategy Development Methodology Using Maximum A Posteriori Bayesian Estimation. *Ther Drug Monit* 2011; **33**: 133-46.

24. Lodise TP, Drusano GL, Zasowski E et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2014; **59**: 666-75.

25. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract* 2012; **120**: c179-84.

26. Rhodes NJ, O'Donnell JN, Lizza BD et al. Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse. *Antimicrobial agents and chemotherapy* 2016; **60**: 838-44.

27. Zhang Z. Model building strategy for logistic regression: purposeful selection. *Ann Transl Med* 2016; **4**: 111.

28. Ainsworth SB. Neonatal Formulary 7: Drug Use in Pregnancy and the First Year of Life. UK: Wiley Blackwell. BMJ., 2014; 520.

29. Pediatrics AAo. Red Book: Report of the Committee on Infectious Diseases. In: Kimberlin DW BM, Jackson MA, Long SS, ed. USA: Itasca, IL: American Academy of Pediatrics, 2018; 918.

30. Fenton TR, Sauve RS. Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart. *Eur J Clin Nutr* 2007; **61**: 1380-5.

31. Le J, Ny P, Capparelli E et al. Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. *J Pediatric Infect Dis Soc* 2015; **4**: e109-e16.

32. Stojanovic V, Barisic N, Milanovic B et al. Acute kidney injury in preterm infants admitted to a neonatal intensive care unit. *Pediatr Nephrol* 2014; **29**: 2213-20.

33. Sinclair EA, Yenokyan G, McMunn A et al. Factors associated with acute kidney injury in children receiving vancomycin. *The Annals of pharmacotherapy* 2014; **48**: 1555-62.

34. Le J, Vaida F, Nguyen E et al. Population-Based Pharmacokinetic Modeling of Vancomycin in Children with Renal Insufficiency. *J Pharmacol Clin Toxicol* 2014; **2**: 1017-26.

35. Hahn A, Frenck RW, Allen-Staat M et al. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia. *Ther Drug Monit* 2015; **37**: 619-25.

36. Lestner JM, Hill LF, Heath PT et al. Vancomycin toxicity in neonates: a review of the evidence. *Curr Opin Infect Dis* 2016; **29**: 237-47.

37. Wang J, Zhang H, Yan J et al. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians* 2020: 1-10.

Figures



Figure 1 Study flow



Figure 2 Goodness-of-fit plot of the final established Pop-PK model.

(a) Population predictions vs. observations. (b) Individual predictions (IPRED) vs. observations. The black solid lines are the reference lines, and black dashed lines are the loess smooth lines.



Figure 3. Normalized prediction distribution error (NPDE) plots for the final model.

(a) Histogram of NPDE values; (b) NPDE vs. the probability density. Black dashed lines, theoretical distribution. Blue dashed line, empirical distribution. (c) Scatter plot of the time vs. NPDE; (d) Scatterplot of serum concentrations (Cc) vs. NPDE. Blue filled dots, observed data; Black dashed lines, theoretical mean; Blue solid lines, empirical percentiles of observations; Blue-shaded area, 95% CI for the 5th and 95th percentiles of the predicted values. Pink-shaded area, 95% CI for the 50th percentiles of the predicted values; Red-shaded area, outliers. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.



Figure 4. Receiver operating characteristic (ROC) curves.

(a) ROC curves of $AUC_{0\text{-}24}$, $AUC_{24\text{-}48}$ and $AUC_{0\text{-}48}$ for prediction of AKI. (b) ROC curves of $AUC_{0\text{-}24}$/MIC, $AUC_{24\text{-}48}$/MIC and $AUC_{0\text{-}48}$/MIC for prediction of efficacy. AUC_{ROC}, area under the ROC curve.

Tables

Table 1. The estimates of the final model and 2000 bootstrap results

Parameter[a]	Final model		Bootstrap		Bias (%)[c]
	Estimate	RSE (%)[b]	Median	2.5%~97.5%	
Structure model parameter					
V_{pop} (L)	0.86	3.02	0.87	0.80 ~ 0.93	0.82
CL_{pop} (L/h)	0.09	2.11	0.09	0.08 ~ 0.09	0.69
beta1	2.35	1.20	2.29	1.94 ~ 2.66	-2.77
beta2	0.18	3.41	0.18	0.09 ~ 0.28	4.55
F_{VAS}	0.86	0.34	0.85	0.77 ~ 0.94	-1.28
Inter-individual variabilty					
V (%CV)	11%	24.20	14%	0.09 ~ 0.20	24.11
CL (%CV)	24%	6.85	23%	0.20 ~ 0.26	-2.11
Residual variability					
Proportional (%CV)	0.21	4.82	0.21	0.18 ~ 0.24	-0.47

$$V = V_{pop} \times \left(\frac{cWT}{1.5}\right)$$

$$CL = CL_{pop} \times \left(\frac{cWT}{1.5}\right)^{0.75} \times \left(\frac{PMA}{32}\right)^{beta1} \times \left(\frac{30}{SCR}\right)^{beta2} \times F_{VAS}$$

V_{pop}, population mean estimate for volume of distribution in a subject with a body weight of 1.5 kg; cWT, current body weight; CL_{pop}, population mean estimate for vancomycin clearance in a subject with a body weight of 1.5 kg; PMA, postmenstrual age; SCR, serum creatinine; F_{VAS}. scaling factor of concomitant use of vasoactive drugs.

[a]V (%CV), interindividual variability of volume of distribution; CL (%CV), interindividual variability of vancomycin clearance.

[b]RSE, relative standard error.

[c]Bias%, relative bias of estimates by Monolix to the median estimates by 2000 bootstrap procedures. The rate of bias in fixed effects less than 5% was thought acceptable. It was calculated by the formula

$$Bias(\%) = \frac{Median_{bootstrap} - Median_{final}}{Median_{final}} \times 100\%$$

.

Table 2. Comparisons of demographic and PK/PD characteristics between patients with and without AKI / patients with and without effective treatment.

	Non-AKI patients (N=175) median (range/proportion)	AKI patients (N=7) median (range/proportion)	P	Effective patients (N=35) median (range/proportion)	Ineffective patients (N=7) median (range/proportion)	P
Maturation						
Gender	98/77(male/female)	4/3(male/female)	1.00	18/17(male/female)	5/2(male/female)	0.43
Gestational age (weeks)	30.43(22.29~41.29)	33.86(24.71~40.00)	0.20	31.00(24.43~40.00)	29.71(26.29~33.29)	0.32
Postnatal age (weeks)	1.71(0.14~12.43)	0.29(0.43~1.71)	<0.01	2.14 (0.43~4.86)	2.29 (0.57~3.71)	1.00
Postmenstrual age (weeks)	33.00(22.29~44.43)	34.00(26.29~40.57)	0.66	33.14(26.00~40.71)	32.14(26.71~34.43)	0.41
Birth weight (kg)	1.35(0.55~4.40)	1.74(0.77~3.05)	0.43	1.37(0.70~3.03)	0.95(0.77~1.18)	< 0.01
Current weight (kg)	1.54(0.55~5.57)	1.77(0.90~3.02)	0.71	1.50(0.78~2.98)	1.18(0.74~1.45)	< 0.01
Renal Function						
Serum creatinine (μmol/L)	28.20(3.90~77.50)	45.70(32.80~75.80)	<0.01	24.30(9.60~55.21)	22.80(10.70~44.40)	0.84
Creatinine clearance [(mL/min)/1.73m^2]	33.53(9.69~142.18)	24.60(15.01~29.97)	<0.05	38.40(17.55~81.95)	36.71(22.37~51.40)	0.60
PK/PD Parameters						
Daily dose (mg/kg)	29.79(12.96~62.07)	28.80(11.41~46.69)	0.28	29.68(16.25~45.30)	29.55(18.92~45.52)	0.65
Clearance [L/(h·kg)]	0.07(0.02~0.16)	0.03(0.03~0.04)	<0.01	0.06(0.04 ~ 0.16)	0.06(0.05 ~ 0.13)	0.77
Vancomycin trough (mg/L)	10.67(3.11~33.01)	23.50(13.88~51.36)	<0.01	10.76(3.14~23.98)	9.72(6.42~12.76)	0.22
AUC_{0-24} (mg·h/L)	360(191~617)	489(270~788)	0.08	366(212~597)	285(238~412)	< 0.05

AUC_{24-48} (mg·h/L)	531(265~978)	623(389~1066)	0.12	565(309~978)	436(320~546)	< 0.05
AUC_{0-48} (mg·h/L)	891(456~1575)	1112(659~1854)	0.11	928(520~1575)	721(557~899)	<0.05
AUC_{0-24}⩾485(mg·h/L)	17 (9.71%)	4 (57.1%)	<0.01	/	/	/
AUC_{24-48}⩾622(mg·h/L)	42 (24.0%)	4 (57.1%)	0.07	/	/	/
AUC_{0-48}⩾1077(mg·h/L)	36 (20.6%)	4 (57.1%)	<0.05	/	/	/
MIC (mg/L)	/	/	/	2.0 (0.5~2.0)	2.0 (2.0~2.0)	0.12
AUC_{0-24}/MIC⩾234	/	/	/	30 (85.7%)	1 (14.3%)	<0.01
AUC_{24-48}/MIC⩾278	/	/	/	22 (62.9%)	0 (0.00%)	<0.01
AUC_{0-48}/MIC⩾450	/	/	/	23 (65.7%)	0 (0.00%)	<0.01
Comorbidities						
Patent ductus arteriosus	76 (43.4%)	7 (100.0%)	<0.01	10 (28.6%)	3 (42.9%)	0.66
Pneumonia	74 (42.3%)	4 (57.1%)	0.46	8 (22.9%)	3 (42.9%)	0.35
Bronchopulmonary dysplasia	41 (23.4%)	2 (28.6%)	0.67	5 (14.3%)	2 (28.6%)	0.58
Meningitis	36 (20.6%)	1 (14.3%)	1.00	4 (11.4%)	0 (0.00%)	1.00
Neonatal necrotic enterocolitis	31 (17.7%)	2 (28.6%)	0.61	5 (14.3%)	0 (0.00%)	0.57
Persistent pulmonary hypertension of newborn	14 (8.00%)	2 (28.6%)	0.12	2 (5.71%)	0 (0.00%)	1.00
Co-medication						
Meropenem	82 (46.9%)	7 (100.0%)	<0.01	11 (31.4%)	2 (28.6%)	1.00
Vasoactive drugs[a]	33 (18.9%)	6 (85.7%)	<0.01	2 (5.71%)	1 (14.3%)	0.43
Furosemide	26 (14.9%)	4 (57.1%)	<0.05	1 (2.86%)	1 (14.3%)	0.31
Ibuprofen	8 (4.57%)	0 (0.00%)	1.00	1 (2.86%)	0 (0.00%)	1.00
Outcome						
Mortality	13 (7.43%)	2 (28.6%)	0.10	0 (0.00%)	3 (42.9%)	< 0.01

[*]Continuous variables were compared by Mann-Whitney U tests, and dichotomous variables by Fisher exact tests.

[a]Vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.

[b]AKI, acute kidney injury.

Table 3. Results of multivariate regression analysis.

Variable	adjusted OR (95% CI)	P
AKI analysis		
$AUC_{0-24} \geqslant 485$ (mg·h/L)	11.31 (1.95,65.54)	<0.01
Concomitant use of VAS[a]	24.23 (2.65,221.76)	<0.01
Efficacy analysis		
$AUC_{0-24}/MIC \geqslant 234$	36 (3.54,365.98)	<0.01

[a]VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.

Table 4. Results of model informed dosing regimens.

cWT[a] (kg)	PMA[b] (weeks)	SCR[c] (μmol/L)	Patients without VAS [d] (mg/kg)	Patients with VAS (mg/kg)
0.7~0.99	25~27	10	17.5~20, q24h	15~17.5, q24h
		25	15~17.5, q24h	15~17.5, q24h
		45	15~17.5, q24h	12.5~15, q24h
		60	15~17.5, q24h	12.5~15, q24h
		90	12.5~15, q24h	12.5~15, q24h
1.0 ~ 1.69	28 ~ 31	10	15~17.5, q18h	17.5~20, q24h
		25	12.5~15, q18h	17.5~20, q24h
		45	12.5~15, q18h	15~17.5, q24h
		60	12.5~15, q18h	15~17.5, q24h
		90	10~12.5, q18h	15~17.5, q24h
1.7 ~ 2.69	32 ~ 36	10	15~17.5, q12h	12.5~15, q12h
		25	12.5~15, q12h	10~12.5, q12h
		45	10~12.5, q12h	10~12.5, q12h
		60	10~12.5 q12h	10~12.5, q12h
		90	10~12.5, q12h	10, q12h
2.7 ~ 3.69	37 ~ 41	10	17.5~20, q12h	15~17.5, q12h
		25	15~17.5, q12h	12.5~15, q12h
		45	12.5~15, q12h	12.5~15, q12h
		60	12.5~15, q12h	12.5~15, q12h
		90	12.5~15, q12h	10~12.5, q12h
3.7 ~ 4.6	42 ~ 46	10	12.5~15, q8h	17.5~20, q12h
		25	12.5~15, q8h	15~17.5, q12h
		45	10~12.5, q8h	15, q12h
		60	10~12.5, q8h	15, q12h
		90	10, q8h	12.5~15, q12h

[a]cWT, current body weight.

[b]PMA, postmenstrual age.

[c]SCR, serum creatinine.

[d]VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.